Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy

Back

ESC Professional Premium Access

Real-world effectiveness of tafamidis in a contemporary, matched cohort of patients with variant and wild-type transthyretin amyloid cardiomyopathy

Session: New perspectives in cardiology (1) - Cardiac amyloidosis (1)

Topic: Infiltrative Myocardial Disease

Speaker: Doctor M. Maurer (New York, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Mathew Maurer

Columbia University Irving Medical Centre, New York (United States of America)

19 presentations

5 followers

9 more presentations in this session

Discussant - Cardiac amyloidosis (1)

Access

The role of nutritional status, measured by serum albumin, as a prognostic factor in wild-type transthyretin amyloidosis

Speaker: Mr S. Decotto (Buenos Aires, AR)

Clinical characteristics and follow-up outcomes of patients with wild-type transthyretin amyloidosis: comparison of the pre- and post-bone scintigraphy eras in a Latin American center.

Speaker: Miss P. Domenech (Buenos Aires, AR)

Wild-type transthyretin cardiac amyloidosis: sex differences in prevalence, phenotype, and prognosis

Speaker: Assistant Professor A. Zaroui (Creteil, FR)

Predictors of major adverse cardiovascular events in patients with wild-type transthyretin amyloid cardiomyopathy: insights from a regional hospital experience

Speaker: Doctor A. Martins (Leiria, PT)

Access the full session

New perspectives in cardiology (1) - Cardiac amyloidosis (1)

Speakers: Doctor M. Maurer, Mr S. Decotto, Miss P. Domenech, Assistant Professor A. Zaroui, Doctor A. Martins

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources